# OnCo record paper-talapro-2-lancet-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-talapro-2-lancet-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-talapro-2-lancet-2023" ;
  schema:name "Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial"@en ;
  schema:description "Published report from the TALAPRO-2 trial registered as NCT03395197, in The Lancet (2023), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-talapro-2-lancet-2023/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(23)01055-3>, <https://pubmed.ncbi.nlm.nih.gov/37285865/>, <https://europepmc.org/article/MED/37285865>, <https://clinicaltrials.gov/study/NCT03395197> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(23)01055-3> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Agarwal N, Azad AA, Carles J, et al." ;
  onco:trials <https://onco.cc/trials/talapro-2/> ;
  onco:journals <https://onco.cc/journals/lancet/> .